Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors

Int J Mol Sci. 2021 Apr 27;22(9):4546. doi: 10.3390/ijms22094546.

Abstract

Ubiquitylation and deubiquitylation are reversible protein post-translational modification (PTM) processes involving the regulation of protein degradation under physiological conditions. Loss of balance in this regulatory system can lead to a wide range of diseases, such as cancer and inflammation. As the main members of the deubiquitinases (DUBs) family, ubiquitin-specific peptidases (USPs) are closely related to biological processes through a variety of molecular signaling pathways, including DNA damage repair, p53 and transforming growth factor-β (TGF-β) pathways. Over the past decade, increasing attention has been drawn to USPs as potential targets for the development of therapeutics across diverse therapeutic areas. In this review, we summarize the crucial roles of USPs in different signaling pathways and focus on advances in the development of USP inhibitors, as well as the methods of screening and identifying USP inhibitors.

Keywords: USP inhibitors; drug screening; signaling pathways; ubiquitin-specific peptidases.

Publication types

  • Review

MeSH terms

  • Deubiquitinating Enzymes / metabolism
  • Drug Evaluation, Preclinical
  • Humans
  • Neoplasms / metabolism
  • Protein Processing, Post-Translational / physiology
  • Proteolysis
  • Signal Transduction
  • Ubiquitin / metabolism
  • Ubiquitin-Specific Proteases / antagonists & inhibitors*
  • Ubiquitin-Specific Proteases / metabolism*
  • Ubiquitination / physiology

Substances

  • Ubiquitin
  • Deubiquitinating Enzymes
  • Ubiquitin-Specific Proteases